Tiago Tizziani

Dr. Tiago Tizziani

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MBMariana Bottamedi
Mariana Bottamedi
MNMarcus Vinicius Nascimento
Marcus Vinicius Nascimento
EFEduarda Fratoni
Eduarda Fratoni
YMYeo Jim Kinoshita Moon
Yeo Jim Kinoshita Moon
LFLarissa Faqueti
Larissa Faqueti
BMBeatriz Garcia Mendes
Beatriz Garcia Mendes

16 March 2024 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
SCSabrina Barros Cavalcante
Sabrina Barros Cavalcante
ASAndré Felipe da Silva
André Felipe da Silva
LPLucas Pradi
Lucas Pradi
JLJhuly Wellen Ferreira Lacerda
Jhuly Wellen Ferreira Lacerda
Tiago TizzianiTiago Tizziani
Tiago Tizziani
DRDiogo Robl
Diogo Robl

1 April 2022 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
LCLuana N.O. Leal da Cunha
Luana N.O. Leal da Cunha
Tiago TizzianiTiago Tizziani
Tiago Tizziani
GSGabriella B. Souza
Gabriella B. Souza
MMMonalisa A. Moreira
Monalisa A. Moreira
JNJosé S.S. Neto
José S.S. Neto
Louis Pergaud SandjoLouis Pergaud Sandjo
Louis Pergaud Sandjo
Background: COVID-19 is still causing long-term health consequences, mass deaths, and collapsing healthcare systems around the world. There are no efficient drugs for its treatment. However, previous studies revealed that SARS-CoV-2 and SARS-CoV have 96% and 86.5% similarities in cysteine proteases (3CLpro) and papain-like protease (PLpro) sequences, respectively. This resemblance could be important in the search for drug candidates with antiviral effects against SARS-CoV-2. Objective: This paper is a compilation of natural products that inhibit SARS-CoV 3CLpro and PLpro and, concomitantly, reduce inflammation and/or modulate the immune system as a perspective strategy for COVID-19 drug discovery. It also presents in silico studies performed on these selected natural products using SARS-CoV-2 3CLpro and PLpro as targets to propose a list of hit compounds. Methods: The plant metabolites were selected in the literature based on their biological activities on SARS-CoV proteins, inflammatory mediators, and immune response. The consensus docking analysis was performed using four different packages. Results: Seventy-nine compounds reported in the literature with inhibitory effects on SARS-CoV proteins were reported as anti-inflammatory agents. Fourteen of them showed immunomodulatory effects in previous studies. Five and six of these compounds showed significant in silico consensus as drug candidates that can inhibit PLpro and 3CLpro, respectively. Our findings corroborated recent results reported on anti-SARS-CoV-2 in the literature. Conclusion: This study revealed that amentoflavone, rubranoside B, savinin, psoralidin, hirsutenone, and papyriflavonol A are good drug candidates for the search of antibiotics against COVID-19.

14 February 2023 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
OFOctavio L. Guterres Fernandes
Octavio L. Guterres Fernandes
Tiago TizzianiTiago Tizziani
Tiago Tizziani
BDBibiana P. Dambrós
Bibiana P. Dambrós
Natália Ferreira De SousaNatália Ferreira De Sousa
Natália Ferreira De Sousa
CPCarime L. Mansur Pontes
Carime L. Mansur Pontes
Louis Pergaud SandjoLouis Pergaud Sandjo
Louis Pergaud Sandjo

18 October 2022 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
VMValkiria Machado
Valkiria Machado
ACArthur R. Cenci
Arthur R. Cenci
KTKerolain F. Teixeira
Kerolain F. Teixeira
LSLarissa Sens
Larissa Sens
Tiago TizzianiTiago Tizziani
Tiago Tizziani
AOAldo Oliveira
Aldo Oliveira
Alzheimer's disease (AD) is a neurodegenerative disease that is characterized as the main dementia in the elderly. Eighteen pyrazolines were synthesized and evaluated for their inhibitory effects against acetylcholinesterase (AChE) in vitro. Possible interactions between pyrazolines and the enzyme were explored by in silico experiments. Compound 2B of the series was the most active pyrazoline with an IC50 value of 58 nM. Molecular docking studies revealed two important π–π interactions with residues Trp 286 and Tyr 341. A correlation between the HOMO-1 surface and AChE inhibition was observed. ADMET assays demonstrated a good profile for compound 2B. From the abovementioned findings, a new avenue of compound 2B analogues could be explored to develop anti-AD agents.

1 April 2018 in Biochemical Systematics and Ecology
Verified
Journal Article
Closed access
Tiago TizzianiTiago Tizziani
Tiago Tizziani
DVDalila Venzke
Dalila Venzke
ARAna Paula Ruani
Ana Paula Ruani
MPMarcos Pereira
Marcos Pereira
GMGustavo Amadeu Micke
Gustavo Amadeu Micke
IBInês Maria Costa Brighente
Inês Maria Costa Brighente